Transplantation of amniotic membrane‐derived multipotent cells ameliorates and delays the progression of chronic kidney disease in cats

Abstract

Contents Chronic kidney disease ( CKD ) is a common clinical condition in domestic cats, characterized by tubulointerstitial, vascular and glomerular inflammation and severe fibrosis. Studies in rodent model of induced CKD have shown a decrease and stabilization of the clinical condition. In this study was evaluated the safety and effect of intrarenal and intravenous infusion of allogeneic mesenchymal stem cells ( AMSC s) derived from feline amniotic membrane in cats with naturally occurring CKD . Cat AMSC s were harvested after mechanical and enzymatic digestion of amnion. A healthy cat received intrarenal injection of AMSC s guided by ultrasound in both kidneys (5 × 10 5 cells/kidney). Nine cats with CDK received repeated intravenous infusions of AMSC s (2 × 10 6 cells × 2 treatments). The clinical parameters of healthy cat did not change, but sedation and general anaesthesia was required. The number of interventions stressed the animal, and he developed transient haematuria after AMSC injection. Cats with CDK registered a significant improvement of renal function (decrease in serum creatinine and urine protein concentrations and increase in urine specific gravity). The kidney architecture and morphology did not change following the treatment. The feline AMSC s have a renoprotective effect and improve renal function in cats with naturally occurring CKD , stabilizing the clinical condition and disease progression. Thus, intravenous injection of AMSC s may be an important tool to provide welfare in cats with chronic kidney disease.